Idexx Laboratories (IDXX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Sales | 4,303,702 | 3,897,504 | 3,660,953 | 3,367,324 | 3,215,360 |
| Cost of Goods | 1,644,123 | 1,518,577 | 1,470,983 | 1,362,986 | 1,325,928 |
| Gross Profit | 2,659,579 | 2,378,927 | 2,189,970 | 2,004,338 | 1,889,432 |
| Operating Expenses | 1,299,671 | 1,251,167 | 1,093,825 | 1,106,559 | 958,332 |
| Operating Income | 1,360,031 | 1,128,337 | 1,097,128 | 898,765 | 932,028 |
| Interest Expense | 38,852 | 31,205 | 41,581 | 39,858 | 29,808 |
| Other Income | 3,010 | 12,699 | 5,629 | 1,065 | 434 |
| Pre-tax Income | 1,324,189 | 1,109,831 | 1,061,176 | 859,972 | 902,654 |
| Income Tax | 264,725 | 221,964 | 216,134 | 180,883 | 157,810 |
| Net Income Continuous | 1,059,464 | 887,867 | 845,042 | 679,089 | 744,844 |
| Minority Interests | N/A | N/A | N/A | N/A | -1 |
| Net Income | $1,059,464 | $887,867 | $845,042 | $679,089 | $744,845 |
| EPS Basic Total Ops | 13.17 | 10.77 | 10.17 | 8.12 | 8.74 |
| EPS Basic Continuous Ops | 13.17 | 10.77 | 10.17 | 8.12 | 8.74 |
| EPS Diluted Total Ops | 13.08 | 10.67 | 10.06 | 8.03 | 8.60 |
| EPS Diluted Continuous Ops | 13.08 | 10.67 | 10.06 | 8.03 | 8.60 |
| EPS Diluted Before Non-Recurring Items | 13.08 | 10.67 | 10.06 | 8.03 | 8.60 |
| EBITDA(a) | $1,505,214 | $1,258,273 | $1,212,036 | $1,010,665 | $1,036,624 |